The overall objectives for the studies proposed in this project is to delineate the mechanisms by which human Natural Killer cells are tolerant to normal autologous somatic cells;and define the conditions leading to NK cell activation by allogeneic cells. It has been proposed that NK cells in normal individuals achieve self-tolerance by endowing functional competence only to the inhibitory Killer immunoglobulin-like Receptors (KIR) for which they exhibit cognate HLA ligands. We hypothesize that engrafting NK cells following allogeneic hematopoietic stem cell transplantation (HCT) acquire tolerance to self through selective anergy of non-self inhibitory KIR. Prior to this acquisition of tolerance, donor NK alloreactivity due to missing KIR ligand in the host may be most evident. We also hypothesize that recognition of HLA class I by activating KIR only occurs when the HLA molecule is presented as an alloantigen,Jn contrast, when the HLA molecule is a self HLA molecule, the activating KIR is tolerized or unresponsive. These hypotheses will be tested in four specific aims: #1: Determine how NK alloreactivity is influenced by presence of activating KIRs KIR2DS2, 2DS1 and 3DS1 in individuals with different combinations of KIRhaplotypes andHLAclass I genotypes. This will beachieved bydetermining (a) if presence of the activating KIRs 2DS1, 2DS2 or 3DS1 correlates with a NK cell mediated alloresponse with specificity for the HLA-Cw and HLA-Bw4 KIR-ligand groups and (b) determine the functional NK phenotype in donors with the genes for the activating KIRs 2DS1, 2DS2 or 3DS1 and the corresponding KIR-HLA ligand group as self MHC antigen. #2: Determine if the development of NK cell alloreactivity and self tolerance associated with activating KIRs develops gradually over time during the period of engraftment. We will also examine if engrafting NK cells at any time display alloreactivity that deviates from donor NK alloreactivity. #3: (a) Determine acquisition of NK tolerance to self during'engraftment. We will determine if an initial period of hyper-responsiveness of inhibitory KIR is followed by selective anergy of non-self MHC-specific KIR. (b) Determine if the presence of T-cells in the allograft affects inhibitory KIR-mediated NK response. #4: Determine the acquisition of NK receptors to HLA class I during NK development in vitro. Wewill investigate NK development ex vivo from CD34 cells obtained from Cord Blood and other sources. We will determine the sequential acquisition of NK receptors, and differential acquisition of receptors within the same receptor family;determine their acquisition of function, tolerance to self and allogeneic reactivity. We will determine if these developmental patterns are affected by the HLA class I phenotype expressed in the stromal culture environment. Relevance: These studies will facilitate development of new methods for donor selection for patients with leukemia and for treatment with NK cell infusions post transplantation to enhance engraftment and leukemia resistance.

Public Health Relevance

These studies will facilitate development of new methods for donor selection for patients with leukemia and for treatment with NK cell infusions post transplantation to enhance engraftment and leukemia resistance.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA023766-33
Application #
8245880
Study Section
Special Emphasis Panel (ZCA1)
Project Start
1998-09-01
Project End
2013-02-28
Budget Start
2011-03-21
Budget End
2013-02-28
Support Year
33
Fiscal Year
2011
Total Cost
$269,527
Indirect Cost
Name
Sloan-Kettering Institute for Cancer Research
Department
Type
DUNS #
064931884
City
New York
State
NY
Country
United States
Zip Code
10065
Moskowitz, Craig H (2018) Should all patients with HL who relapse after ASCT be considered for allogeneic SCT? A consult, yes; a transplant, not necessarily. Blood Adv 2:821-824
Kim, Seong Jin; Huang, Yao-Ting; Foldi, Julia et al. (2018) Cytomegalovirus resistance in CD34+ -selected hematopoietic cell transplant recipients. Transpl Infect Dis 20:e12881
Maslak, Peter G; Dao, Tao; Bernal, Yvette et al. (2018) Phase 2 trial of a multivalent WT1 peptide vaccine (galinpepimut-S) in acute myeloid leukemia. Blood Adv 2:224-234
DeFilipp, Zachariah; Peled, Jonathan U; Li, Shuli et al. (2018) Third-party fecal microbiota transplantation following allo-HCT reconstitutes microbiome diversity. Blood Adv 2:745-753
Haak, Bastiaan W; Littmann, Eric R; Chaubard, Jean-Luc et al. (2018) Impact of gut colonization with butyrate-producing microbiota on respiratory viral infection following allo-HCT. Blood 131:2978-2986
Boudreau, Jeanette E; Hsu, Katharine C (2018) Natural Killer Cell Education and the Response to Infection and Cancer Therapy: Stay Tuned. Trends Immunol 39:222-239
Lin, Richard J; Ho, Caleb; Hilden, Patrick D et al. (2018) Allogeneic haematopoietic cell transplantation impacts on outcomes of mantle cell lymphoma with TP53 alterations. Br J Haematol :
Malard, Florent; Labopin, Myriam; Cho, Christina et al. (2018) Ex vivo and in vivo T cell-depleted allogeneic stem cell transplantation in patients with acute myeloid leukemia in first complete remission resulted in similar overall survival: on behalf of the ALWP of the EBMT and the MSKCC. J Hematol Oncol 11:127
Luduec, Jean-BenoƮt Le; Kudva, Anupa; Boudreau, Jeanette E et al. (2018) Novel multiplex PCR-SSP method for centromeric KIR allele discrimination. Sci Rep 8:14853
Shah, Gunjan L; Moskowitz, Craig H (2018) Transplant strategies in relapsed/refractory Hodgkin lymphoma. Blood 131:1689-1697

Showing the most recent 10 out of 452 publications